Evidence map›Paper›PMID 31223447›Full record

ArticleACS medicinal chemistry letters2019

Discovery of a Lead Triphenylethanamine Cholesterol Ester Transfer Protein (CETP) Inhibitor.

Heather J Finlay, Ji Jiang, Richard Rampulla, Mark E Salvati, Jennifer X Qiao, Tammy C Wang, R Michael Lawrence, Lalgudi S Harikrishnan, Muthoni G Kamau, David S Taylor and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Heather J FinlayDepartments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
Ji JiangDepartments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
Richard RampullaDepartments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
Mark E SalvatiDepartments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
Jennifer X QiaoDepartments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
Tammy C WangDepartments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
R Michael LawrenceDepartments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
Lalgudi S HarikrishnanDepartments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
Muthoni G KamauDepartments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
David S TaylorDepartments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
Alice Ye A ChenDepartments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
Xiaohong YinDepartments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
Christine S HuangDepartments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
Ming ChangDepartments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
Xue-Qing ChenDepartments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
Paul G SlephDepartments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
Carrie XuDepartments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
Julia LiDepartments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
Paul LevesqueDepartments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
Leonard P AdamDepartments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.
Ruth R WexlerDepartments of Discovery Chemistry, Biology, Preclinical Candidate Optimization, Pharmaceutics, and Bioanalytical Sciences, Bristol-Myers Squibb, Research and Development, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lead optimization of the diphenylpyridylethanamine (DPPE) and triphenylethanamine (TPE) series of CETP inhibitors to improve their pharmaceutical profile is described. Polar groups at the

Identifiers

PMID31223447
PMCPMC6580557

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.